3-((4-Bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide

Base Information

• Chemical Name: 3-((4-Bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide
• CAS No.: 252003-65-9
• Molecular Formula: C20H24BrF2N5O3S
• Molecular Weight: 532.409
• UNII: W1B375O5M2
• DSSTox Substance ID: DTXSID00179866
• Wikidata: Q27076896
• NCI Thesaurus Code: C93263
• Pharos Ligand ID: 62RX24JRAPRP
• Metabolomics Workbench ID: 153845
• ChEMBL ID: CHEMBL253969
• Mol file: 252003-65-9.mol

Synonyms:3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide;CP 547,632;CP 547632;CP-547,632;CP-547632;CP547,632;CP547632

Chemical Property of 3-((4-Bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide

Chemical Property:

• Boiling Point: 548.601 °C at 760 mmHg
• PKA: 12.50±0.70(Predicted)
• Flash Point: 285.584 °C
• Density: 1.533 g/cm³
• Storage Temp.: 2-8°C
• XLogP3: 3.7
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 10
• Exact Mass: 531.07513
• Heavy Atom Count: 32
• Complexity: 622

Purity/Quality:

99% ^*data from raw suppliers

3-((4-Bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide 95+% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1CCN(C1)CCCCNC(=O)NC2=C(C(=NS2)OCC3=C(C=C(C=C3F)Br)F)C(=O)N
• Recent ClinicalTrials: Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.
• Recent EU Clinical Trials: A Randomized, Double Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Na?ve Participants with Neovascular Age-Related Macular Degeneration (AMD)
• Description: CP 547,632 is an orally bioavailable and potent inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and basic fibroblast growth factor (bFGF) with IC50 values of 11 and 9 nM, respectively, in an enzyme assay. It is selective for VEGFR2 and bFGF over EGFR, PDGF receptor β (PDGFRβ), and related tyrosine kinases. CP 547,632 inhibits VEGFR2 autophosphorylation induced by VEGF in porcine aortic endothelial cells transfected with VEGFR2 (IC50 = 6 nM) and in a xenograft mouse model using NIH3T3/H-Ras cells (EC50 = 590 nM). It decreases angiogenesis induced by VEGF or bFGF and suppresses tumor growth in athymic mice.

Technology Process of 3-((4-Bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide

There total 3 articles about 3-((4-Bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 76.0%

3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid methyl ester → 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-4-isothiazolecarboxamide (252003-65-9)

Guidance literature:

With ammonia; In tetrahydrofuran; methanol; at 0 - 40 ℃; for 114h; under 517.162 - 2585.81 Torr;

Reference yield:

4-Pyrrolidino-butylamin (24715-90-0) + [3-(4-bromo-2,6-difluoro-benzyloxy)4-carbamoyl-isothiazol-5-yl]-carbamic acid phenyl ester → 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-4-isothiazolecarboxamide (252003-65-9)

Guidance literature:

Reference yield:

→ 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-4-isothiazolecarboxamide (252003-65-9)

Guidance literature:

upstream raw materials:

4-Pyrrolidino-butylamin

Downstream raw materials:

3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-4-isothiazolecarboxamide hydrochloride

Refernces

• 1、 -. "Dosage forms and methods of treatment using VEGFR inhibitors". Page/Page column 6. . Retrieved 2008/06/13.